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Abstract
The kinetic mechanism of action of Draculin on activated Factor X (FXa) is established. Draculin inhibits activated
Factor X within seconds of incubation at near equimolar concentration (2^6 times on molar basis). Fitting the data to the
equation for a tight-binding inhibitor gives a value for Ki(Kd) = 14.8 þ 1.5 nM. The formation of the Draculin^FXa complex
can be explained by a two-step mechanism, where for the first, reversible step, kon = 1.117 ( þ 0.169, S.E.M.)U106 M31 s31
and koff = 15.388 ( þ 1.672)U1033 s31, while for the second, irreversible step, which is concentration-independent, k2 = 0.072
s31. Kd obtained from koff /kon = 13.76 nM. Lineweaver^Burk plot shows a noncompetitive behavior. This noncompetitive
mode of inhibition of Draculin is supported by the observation that Draculin, at concentrations giving complete inhibition,
does not impair binding of p-aminobenzamidine to FXa. Moreover, under the same conditions, Draculin induces 6 14%
decrease of the fluorescence intensity of the p-aminobenzamidine^FXa complex. We conclude that Draculin is a
noncompetitive, tight-binding inhibitor of FXa, a characteristic so far unique amongst natural FXa inhibitors. ß 1999
Elsevier Science B.V. All rights reserved.
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1. Introduction
Activation of Factor X is a common point be-
tween the intrinsic and extrinsic pathway of blood
coagulation [1]. Activated factor X (FXa) is the
sole enzyme that catalyzes the conversion of pro-
thrombin into thrombin, the key enzyme in the co-
agulation cascade; therefore inhibitors of this step
are of considerable mechanistic and pharmacological
interest. In addition to the two known physiological
inhibitors of this serine protease, antithrombin III
(AT-III) and the tissue factor pathway inhibitor
(TFPI), several low molecular mass naturally occur-
0167-4838 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
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Abbreviations: FXa, activated Factor X; FIXa, activated Fac-
tor IX; S.E.M., standard error median; pAB, p-aminobenzami-
dine; BA, benzamidine; AT-III, Antithrombin III; TFPI, tissue
factor pathway inhibitor; TAP, tick anticoagulant peptide;
rTAP, recombinant TAP; AcAP, Ancylostoma caninum anticoa-
gulant peptide; SDS^PAGE, sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis ; HRP, horseradish peroxidase; FCA,
Freund's complete adjuvant; FIA, Freund's incomplete adjuvant
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ring polypeptides inhibitors have been described,
such as Antistasin, a 119-residue protein isolated
from the mexican leech Haementeria o¤cinalis
[2,3] ; the tick anticoagulant peptide (TAP) [4], a
60-amino acid protein derived from the tick Ornitho-
doros moubata ; Ecotin, a periplasmic protein found
in Escherichia coli [5^7]; and the Ancylostoma cani-
num anticoagulant peptide (AcAP) [8]. These pepti-
des behave as reversible, slow tight-binding inhibitors
of FXa, where Antistasin and Ecotin are slowly
cleaved by FXa, while TAP is not a¡ected by the
protease. Recently, we described a new natural
FXa inhibitor, isolated from the saliva of the vam-
pire bat Desmodus rotundus, which was named Dra-
culin. Draculin is a 88.5 kDa glycoprotein which
selectively inhibits both FXa and activated factor
IX (FIXa) [9]. Furthermore, the anticoagulant activ-
ity of Draculin is highly dependent on the proper
glycosylation of the polypeptide backbone [10]. The
results described in this paper indicate that, in con-
trast to other natural FXa inhibitors, Draculin be-
haves as a noncompetitive, tight-binding inhibitor of
FXa.
2. Materials and methods
2.1. Materials and reagents
Hydroxyapatite (Biogel-HTP), acrylamyde and sil-
ver-staining reagents were purchased from Bio-Rad
Laboratories (Richmond, CA, USA). Benzamidine
and p-aminobenzamidine dihydrochloride were
from Sigma (MO, USA). Coagulation factors were
puri¢ed by established procedures by Dr. Rob Wa-
genvoord (Department of Biochemistry, University
of Limburg, The Netherlands). FXa concentration
was measured by titration with p-N-p-guanidoben-
zoate [11]. The activity of FXa was assayed using
the chromogenic substrates S-2222 (Km = 200 WM,
Chromogenix, Sweden), S-2337 (Km = 200 WM,
Kabi Diagnostica, Sweden) and CH3OCO-D-CHG-
Gly-Arg-pNA (Km = 104 WM, Pentapharm). Freund's
complete adjuvant (FCA) was from Calbiochem
(CA, USA) and Freund's incomplete adjuvant
(FIA) was from Gibco (OH, USA). EGGstract pu-
ri¢cation system and Anti-chicken IgY HRP conju-
gate were supplied by Promega (WI, USA). ECL
Western blotting detection reagents were purchased
from Amersham Life Science (UK). All other re-
agents used were of the highest quality commercially
available. For graphics and mathematical ap-
proaches, Origin 5.0 Software was used (Microcal
Software, MA, USA).
2.2. Animals
Vampire bats (Desmodus rotundus) were regularly
captured from wild colonies in the region of Choron|̈
(State of Aragua, Venezuela). The bats were kept in
captivity, in individual cages of the metabolic type
(Acme Metal Products, Chicago, IL, USA), under
controlled light and temperature (25³C). The animals
were maintained on bovine blood anticoagulated
with 3.8% sodium citrate at a ratio of 1:9. Food
was given every 24 h and water was given ad libitum
[12].
2.3. Saliva collection
As shown previously [10], the biological activity of
Draculin is highly dependent on the appropriate gly-
cosylation of the native protein and seriously a¡ected
by the salivation pattern of the animals. Therefore,
for the purpose of the present study, saliva collection
was done as follows: eight to ten animals were sali-
vated, as previously described [10], at 5-day intervals.
Each sample was assayed for protein concentration
and FXa inhibitory activity, and kept at 320³C until
use. Similar batches were pooled and Draculin puri-
¢ed as already described [10]. Under these condi-
tions, the puri¢ed protein obtained had an inhibitory
activity of 4.92 nmol FXa inhibited per mg of Dra-
culin.
2.4. Factor Xa activity
Factor Xa activity was assayed on speci¢c chro-
mogenic substrates. For the microplate assay of FXa
activity, 50 Wl of each of the hydroxyapatite column-
eluted fractions was placed in a well with 100 Wl of
bu¡er A (0.05 M Tris^HCl, 0.1 M NaCl (pH 7.35)
with 0.05% egg albumin), 3 nM FXa and 20 Wl of
4 mM S-2222, in a ¢nal volume of 180 Wl. After
15 min incubation at 37³C the optical density at
405 nm was recorded in a microplate reader
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(EL312e Bio-Kinetics reader microplate, Bio-Tek
Instruments). Continuous assay of FXa activity was
used for quantifying and kinetics studies of the anti-
Xa activity of Draculin. Brie£y, 10^13 nM FXa was
incubated with Draculin for 1 min at 37³C in a cuv-
ette containing bu¡er A. The cuvette was placed in a
home-made ¢xed dual-wavelength photometer (Bio-
chemistry and Instrumental Dept., Univ. of Lim-
burg, The Netherlands) for the continuous recording
of the reaction at 405 nm. The reaction was started
with addition of 35 Wl of S-2337 (¢nal concentra-
tion = 400 WM). The ¢nal volume of the reaction
mix was 500 Wl. For kinetic studies, CH3OCO-D-
CHG-Gly-Arg-pNA, a low-Km substrate, was used
and FXa was in the range of 1^4 nM. The reaction
conditions were as described above.
2.5. p-Aminobenzamidine binding to FXa
Use of p-Aminobenzamidine (pAB) as a £uores-
cent probe for the active site of serine proteases
and its displacement by active site speci¢c ligands
(benzamidine, AT III) has been previously reported
[13,14]. FXa (1 WM) and pAB (75 WM) were incu-
bated in a microcuvette (2 mm wide, 10 mm path)
with bu¡er A (¢nal volume = 500 Wl). The £uores-
cence intensity was measured in a spectro£uoropho-
tometer (RF-1501, Shimadzu) with excitation at
336 nm and emission at 376 nm. Draculin (7 WM)
was added as described in Fig. 6. Benzamidine (1.13
mM) was used as a positive control for pAB dis-
placement.
2.6. HPLC of the Draculin^FXa complex
Draculin and FXa at a ratio of 1:10 were incu-
bated for 10 min at room temperature. A 25-Wl sam-
ple was loaded on a molecular exclusion column
(Protein Pak 300sw, Waters, Millipore, USA). Equi-
libration of the column and elution of the sample
was done with 250 mM phosphate, pH 6.8. Draculin
at the same concentration was run as control. Detec-
tion was monitored at 280 nm.
2.7. E¡ect of factor Xa on Draculin
In order to determine if the interaction of Draculin
with FXa results in cleavage of the inhibitor, 200 nM
FXa and 400 nM Draculin were incubated at room
temperature, and aliquots of the reaction mixture
were removed at various time points and subjected
to Western blotting analysis using anti-Draculin anti-
bodies from egg yolks, obtained as previously de-
scribed [10]. Detection was done using a chemilumi-
nescent method (Amersham Life Science). Factor Xa
and Draculin incubated alone under the same con-
ditions were used as controls.
2.8. Other methods
Protein determination was done by the Coomassie
blue method [15]. SDS^PAGE was done as described
[16]. Gels were stained with Coomassie blue or silver
staining. For Western blotting analysis, appropriate
methods were used [17,18].
Fig. 1. Molecular exclusion HPLC pro¢le of draculin (DRAC) and a mixture of Draculin and FXa (DRAC+FXa). The arrows indi-
cate elution time of markers: 1, catalase 232 kDa; 2, lactate dehydrogenase 140 kDa; 3, phosphorylase b 94 kDa; 4, albumin 67
kDa. The inset corresponds to the HPLC pro¢le of FXa under the same experimental conditions.
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3. Results
3.1. HPLC of the Draculin^FXa complex
As shown in Fig. 1, incubation of Draculin with
an excess of FXa results in a molecular exclusion
pattern in which a new protein peak, with molecular
mass in the range of 130^150 kDa is clearly apparent
(arrow), suggesting a 1:1 complex between Draculin
and FXa, which is not easily dissociated under the
experimental conditions used.
3.2. E¡ect of factor Xa on Draculin
Aliquots from a mixture of Draculin (400 nM) and
FXa (200 nM) were taken after 24, 48 and 90 h of
incubation. Western blotting analysis shows no
change in the apparent molecular mass of Draculin.
Furthermore, degradation products reacting with
anti-Draculin antibodies were not observed (not
shown). These results indicate that Draculin is not
a substrate for FXa.
3.3. E¡ect of Draculin on the progress curve for the
amidolytic activity of FXa
Preincubation of FXa with Draculin inhibits the
catalytic activity of the enzyme in a dose-dependent
manner at concentrations that are comparable to the
total enzyme concentration (Fig. 2). Increasing the
incubation time does not change the degree of inhib-
ition (results not shown). For practical reasons 1 min
incubation time was routinely used. Initial rates were
obtained from the linear (6 25 s) part of the progress
curve in order to avoid the e¡ect of substrate deple-
tion on the linearity of the progress curve also ob-
served in the control assay. The apparent lag phase
shown in the ¢gure at the highest Draculin concen-
tration was not observed in repeated experiments
(n = 10).
From the progress curves shown in Fig. 2, inhib-
ited (Vi) and uninhibited (Vo) initial rates were cal-
culated and then ¢tted by nonlinear regression to the
tight-binding equation [20]:
V i
Vo
 1
2Et
Et3I t3Ki  

I t  Ki 3Et2  4Ki Et
qh i
where Vi/Vo represents the fractional activity of FXa
(inhibited velocity divided by uninhibited velocity),
Et is the total concentration of enzyme, It is inhibitor
concentration and Ki is the dissociation constant
(Fig. 3). The value of Ki(Kd) for the interaction of
Draculin and FXa calculated from this equation is
14.8 þ 1.5 nM.
Fig. 2. Progress curves showing the concentration-dependent ef-
fect of Draculin on the amidolytic activity of FXa (10 nM).
Values in parentheses represent residual activity of FXa (per-
centage). S-2337 (400 WM) was used as substrate. Other condi-
tions as described in Section 2.
Fig. 3. Determination of the intrinsic Ki(Kd) for Draculin. The
inhibitory activity is expressed as the ratio of the inhibited rate
to uninhibited rate (fractional activity). FXa concentration was
10 nM. Substrate used: S-2337 (400 WM). Experimental data
(three determinations) adjusted to Morrison's equation (line)
yield a Ki value of 14.8 þ 1.5 nM.
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3.4. Measurement of rate constants for formation and
dissociation of Draculin^FXa complex
Fig. 4 shows the e¡ect of preincubation of FXa
with Draculin (Xa+Drac+S curve) and the e¡ect of
Draculin addition after 20 s of the start of the reac-
tion (Xa+S+Drac curve). Draculin added to FXa in
the presence of excess substrate (3Km) very rapidly
induces inhibition of the catalytic activity of the en-
zyme (Fig. 4, Xa+S+Drac curve). The level of the
steady state of residual activity is dependent on Dra-
culin concentration as shown in Fig. 2, but is not
dependent on the order of addition of Draculin. Pri-
or incubation of factor Xa with Draculin, for longer
periods of time, as shown in Fig. 4, does not increase
the ¢nal degree of inhibition attained. The inhibition
progress curves, from experiments presented in Fig. 4
(Xa+S+Drac curve), were ¢t to a single exponential
function to obtain the half-time (t1=2) for the inacti-
vation of FXa at di¡erent concentrations of Dracu-
lin. The values for kobs were obtained from
kobs = 0.693/t1=2 [19]. A plot of kobs vs. Draculin con-
centration, ¢tted to a hyperbolic equation (Fig. 5),
shows a linear, concentration-dependent portion fol-
lowed, at Draculin concentrations higher than 50 nM,
by a concentration-independent phase; from the lin-
ear part of the plot (concentration-dependent), the
Fig. 4. Time-dependence of the e¡ect of Draculin on the ami-
dolytic activity of FXa. FXa = 1 nM; Draculin = 10.4 nM; sub-
strate used was CH3OCO-D-CHG-Gly-Arg-pNA = 400 WM.
Steady-state residual activity is independent of the order of ad-
dition and time of incubation of Draculin. Experimental condi-
tions as described in Section 2.
Fig. 5. Dependence of kobs on Draculin concentration. Values of kobs were obtained from experiments as shown in Fig. 4, as described
in Section 3, at various Draculin concentrations. The association rate constant kon was calculated from the slope (kon = kobs/
[Draculin] = 1.117U106 M31 s31. Value for koff , obtained from the y-intercept = koff is 15.388U1033 s31.
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relation kobs = kon [Draculin]+koff allows the calcula-
tion of kon = 1.117 ( þ 0.169)U106 M31 s31 and
koff = 15.388 ( þ 1.672)U1033 s31. Kd, estimated
from koff /kon, equals 13.76U1039 M, which is in ac-
cordance with the Ki calculated from ¢tting the frac-
tional activity (Vi/Vo) data to the tight-binding equa-
tion.
Double reciprocal plot of initial rates of conver-
sion of the low-Km substrate CH3OCO-D-CHG-Gly-
Arg-pNA at di¡erent Draculin concentrations yields
the typical pattern of noncompetitive inhibition (Fig.
6).
3.5. E¡ect of Draculin on the binding of the active-site
directed probe p-aminobenzamidine to FXa
The £uorescent molecule pAB binds to the active
site of serine proteases displaying, upon binding, an
increase in £uorescence yield [13]. pAB can be dis-
placed, with concomitant decrease of £uorescence, by
other compounds that bind to the enzyme active site
(i.e., benzamidine, AT-III for FXa) [14]. As shown in
Fig. 7A, addition of pAB to FXa alone yields a fast
increase in £uorescence and subsequent addition of
BA produces a rapid decrease in £uorescence to al-
most the baseline level. When pAB is added to the
mixture of FXa and Draculin (Fig. 7B), a similar
increase in £uorescence as in the control (Fig. 7A)
is obtained. Furthermore, addition of Draculin to the
pAB^FXa complex, at a concentration that com-
pletely inhibits FXa activity (Fig. 7C), produces at
most a 14% decrease in the £uorescence yield of the
pAB^FXa complex. Increasing time of incubation of
Fig. 6. Double reciprocal plot indicative of the noncompetitive
behavior of Draculin. FXa (4 nM); substrate used was
CH3OCO-D-CHG-Gly-Arg-pNA (Km = 104 WM). (F) Control;
(b) Draculin 21.36 nM; (S) Draculin 32.18 nM; (8) Draculin
41.20 nM. Solid lines represent the best ¢t of the data.
Fig. 7. E¡ect of Draculin on the binding of the active-site directed probe pAB. (A) pAB (75 WM) added to FXa (1 WM) alone; addi-
tion of benzamidine (1.13 mM) displaces pAB and decreases £uorescence to basal level. (B) Addition of pAB to FXa preincubated
with Draculin (7 WM). (C) Addition of Draculin to the pAB^FXa complex decreases by 6 14% the £uorescence yield; addition of
benzamidine to the mixture returns the £uorescence to the initial level.
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FXa with Draculin does not produce any further
changes. The same ¢gure shows that addition of
BA to this mixture decreases the £uorescence yield
as in the absence of Draculin. These results show
that Draculin neither impairs binding of pAB to
the enzyme, nor a¡ects its displacement by BA.
This implies, in agreement with the noncompetitive
kinetic pattern, that Draculin^FXa and Draculin^
FXa^[S] complexes can be simultaneously formed.
The slight decrease in £uorescence yield observed
for the binding of pAB to the Draculin^FXa com-
plex might be due to subtle conformational changes
in the complex that a¡ect the quantum yield of £uo-
rescence.
4. Discussion
Draculin, the anticoagulant glycoprotein isolated
from vampire bat (Desmodus rotundus) saliva, is a
single-chain polypeptide with molecular mass of
88.5 kDa that selectively inhibits FIXa and FXa
[9]. The Lineweaver^Burk pattern, as well as the
lack of interference of Draculin with the active-site
ligand p-aminobenzamidine, clearly indicate that
Draculin acts as a noncompetitive inhibitor of
FXa. The facts that Draculin establishes a relatively
rapid equilibrium with FXa, in a range of similar
concentrations of enzyme and inhibitor, and that
no lag phase is observed at any of the Draculin con-
centrations assayed, allows Draculin to be considered
within the category of tight-binding inhibitors [21].
The lack of cleavage of Draculin by FXa, even after
prolonged periods of time (up to 90 h) agrees with
the noncompetitive mode of inhibition, a fact that
could be potentially advantageous for the vampire
bat feeding. We have previously shown that Draculin
bound to FXa immobilized on A¤Gel is not eluted
even after extensive washings of the matrix [9], sug-
gesting that the FXa^Draculin complex can be rea-
sonably considered as irreversible, under the experi-
mental conditions used. These results, in addition to
those suggesting that Draculin forms an irreversible
complex with FXa, can be explained in part through
the formation of an inactive Draculin^FXa complex
by a two-step mechanism of the type
E I3kon
koff
EIÿ!k2 EI
where formation of EI* is concentration-dependent,
while transformation of EI* into EI is concentration-
independent and essentially irreversible. This result is
in agreement with our present observation that the
Draculin^FXa complex is stable enough to withstand
separation through a molecular exclusion column,
and supports the assumption of irreversibility for
the second step proposed in our kinetic scheme.
Since the formation of EI is an essentially irreversible
step, the value for kobs = 0.072 s31, obtained at the
highest Draculin concentration, closely represents k2,
the rate constant for the concentration independent
step.
These facts distinguish Draculin from other known
natural anti-Xa polypeptides [2^4,7,8], which behave
as competitive, slow, tight-binding inhibitors and, in
the case of Ecotin and Antistasin, are reported to be
slowly cleaved by the enzyme they inhibit. In Table
1, we compare the molecular mass and kinetic pa-
rameters obtained for the interaction of FXa and
Draculin with those published for Antistasin, Ecotin,
rTAP and AcAP. Although kon is in the same range
of values reported for the other inhibitors, the fact
that koff is one to two orders of magnitude faster
makes Draculin a weaker inhibitor (Kd in the nM
range). The noncompetitive behavior of Draculin
may be a plausible explanation for its dual, nonin-
Table 1
Molecular mass and kinetic parameters of Draculin and other natural anti-FXa polypeptides
FXa Inhibitor Molecular mass (kDa) Ki (U1039 M)(Kd) konU106 (M31 s31) koff (s31) Ref.
Draculin 88.5 13.76^14.80 1.117 15.833U1033
Antistasin 15 0.31^0.62 1.2 5.1^5.7U1034 [2]
rTAP 6.8 0.18 2.85 0.554U1033 [22]
Ecotin 16 0.054 1.35 6.5U1035 [6,7]
AcAP 8.7 0.323 ^ ^ [8]
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terfering inhibitory action on both FIXa and FXa
[9], and perhaps a biological advantage to the
blood-feeding need of the vampire bat. Structure^ac-
tivity relationship studies, under way in our labora-
tory, should help to identify portion(s) of the mole-
cule relevant to its interaction with activated factors
IX and X, which may lead to the design of new anti-
coagulant compounds with distinctive inhibitory
mechanisms.
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